We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
74 hedge funds and large institutions have $99.9M invested in Lineage Cell Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
12% more funds holding
Funds holding: 66 → 74 (+8)
1% more capital invested
Capital invested by funds: $98.9M → $99.9M (+$986K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.9% less ownership
Funds ownership: 43.69% → 42.79% (-0.9%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $241K
Holders
74
Holders Change
+8
Holders Change %
+12.12%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
28
Reduced
16
Closed
3
Calls
–
Puts
$241K
Net Calls
-$241K
Net Calls Change
+$633K
Top Buyers
| 1 |
BC
Broadwood Capital
New York
|
+$7.66M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.15M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$585K |
| 4 |
State Street
Boston,
Massachusetts
|
+$277K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$207K |
Top Sellers
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$264K |
| 2 |
Jane Street
New York
|
-$229K |
| 3 |
Citigroup
New York
|
-$111K |
| 4 |
D.E. Shaw & Co
New York
|
-$104K |
| 5 |
FM
Family Management
New York
|
-$53.3K |
